Hypothesis

Intermittent CGRP release from sensory neurons acts as a hormetic signal that activates NRF2-dependent stress resistance through pulsatile calcium‑excitation‑transcription coupling in dorsal horn neurons. Chronic analgesic use blunts these pulses, shifting the system toward maladaptive Cav1.2‑driven transcriptional rewiring and accelerating epigenetic aging.

Mechanistic rationale

• Physiological stressors (exercise, mild heat) evoke short, high‑amplitude CGRP spikes that produce brief Ca²⁺ influx via TRPV1 on central terminals. This Ca²⁺ transient activates CaMKII‑dependent phosphorylation of CREB and, via Cav1.2, drives rapid NRF2 nuclear translocation without sustaining oxidative stress. 1 2
• Analgesics such as morphine or gabapentinoids raise the activation threshold of TRPV1 or dampen presynaptic Ca²⁺ channels, converting physiological spikes into sub‑threshold, prolonged low‑level Ca²⁺ leak. This favors calcineurin‑NFAT signaling, promotes inflammatory gene expression, and reinforces the age‑related increase in TRPV1 expression seen in dorsal horn synapses. 3 4
• The resulting loss of pulsatile NRF2 activation diminishes expression of antioxidant enzymes (HO‑1, NQO1) and reduces mitochondrial hormesis, while chronic low‑level NFAT activity elevates pro‑inflammatory cytokines (IL‑6, TNF‑α) that drive DNA methylation epigenetic clocks. 5

Testable predictions

1. In vivo: Mice receiving chronic low‑dose morphine will show (a) reduced amplitude and frequency of CGRP‑evoked Ca²⁺ transients in spinal dorsal horn (measured by in‑vivo two‑photon imaging), (b) decreased NRF2 target gene expression in lumbar cord and liver, and (c) an accelerated increase in epigenetic age (Horvath mouse clock) compared with saline‑treated controls, despite comparable baseline pain scores.

2. Ex vivo: Dorsal horn slices from morphine‑treated mice will exhibit prolonged, low‑level Ca²⁺ influx upon capsaicin application and heightened calcineurin‑NFAT reporter activity, whereas slices from mice given intermittent CGRP pulses (via optogenetic stimulation of TRPV1⁺ neurons) will display brief Ca²⁺ spikes and robust NRF2 luciferase induction.

3. Human translatable: In a cohort of older adults, regular NSAID or opioid use will correlate with lower plasma CGRP peaks after a standardized cold‑pressor test, reduced NRF2‑dependent gene expression in peripheral blood mononuclear cells, and a higher GrimAge acceleration after adjusting for comorbidities and baseline pain.

Falsifiability

If chronic analgesic administration fails to diminish CGRP‑evoked Ca²⁺ spikes, does not lower NRF2 target expression, and does not accelerate epigenetic age acceleration relative to controls, the hypothesis is refuted. Conversely, demonstration that restoring pulsatile CGRP signaling (e.g., via timed low‑dose capsaicin or chemogenetic activation) rescues NRF2 activity and normalizes epigenetic age in analgesic‑treated animals would strongly support the model.

Proposed experimental workflow

• Animal groups: (1) Saline control, (2) Chronic morphine (10 mg/kg/day, s.c., pump), (3) Morphine + intermittent optogenetic CGRP pulses (5 min 20 Hz daily), (4) Intermittent capsaicin low‑dose (0.1 µg/i.t., 3×/week).

• Readouts: In‑vivo Ca²⁺ imaging (GCaMP6f) in dorsal horn, qPCR/Western for NRF2 targets (HO‑1, NQO1), ELISA for plasma CGRP, RNA‑seq for NFAT‑inflammatory signature, bisulfite sequencing for epigenetic age clocks.

• Statistical plan: Power analysis targeting 80 % detection of 15 % change in GrimAge acceleration (α=0.05, n=10 per group). Mixed‑effects models to account for repeated imaging sessions.

By linking the dynamics of CGRP signaling to NRF2 hormesis and network rewiring, this hypothesis reframes analgesia not as a neutral symptom blocker but as a potential modulator of aging trajectories. It offers a clear, falsifiable path to test whether we are unintentionally silencing a longevity‑promoting stress signal.